NCT06239363Recruiting
Dietary Salicylates and Preeclampsia
Nutritional Sources of Salicylates and Disorders of Placental Angiogenesis in Preeclampsia
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
Preeclampsia (PE) is an important pregnancy complication and cause of maternal and perinatal mortality and morbidity. The underlying etiology and pathophysiology of preeclampsia is incompletely understood but it involves dysfunctional cytotrophoblastic invasion, placental ischemia, and release of inflammatory and endothelial mediators. Placenta dysfunction in PE is related to angiogenic balance. Currently, therapeutic options for the prevention and treatment of PE are limited. It is known that the risk of PE is reduced by low-dose aspirin. Therefore, the influence of salicylates on the development of PE seems to need to be investigated. This project plans to examine the preventive effects of food sources of salicylic acid and compare their effects with aspirin. Therefore, the aim of the present study is thus answer the following questions. whether the maternal dietary intake of salicylates is related to placental angiogenesis; 2. whether naturally occurring salicylates have the same effects on preeclampsia development and placental angiogenesis as aspirin. To answer these questions we plan to carry out a human study with pregnant women. Due to the above the planned research aims to determine the association between maternal dietary intake of salicylates and placental angiogenesis and the risk of preeclampsia development. Although PE remains an incurable disease, the results of this project will enable the development of dietary recommendations for the prevention and treatment of preeclampsia. Moreover, the results of this study may be useful in lowering the cost of maternal and fetal complications from preeclampsia and the cost of their hospitalization.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 23 Jan 2024
- Start date
- 8 Jan 2024
- Primary completion date
- 28 Sept 2027
- Lead sponsor
- Poznan University of Life Sciences
- NCT number
- NCT06239363
What you commit to
- Study type: Observational
- Planned participants: 500
- From 8 Jan 2024 to the primary completion date, 28 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- pregnancies with detectable fetal defects, chromosomal abnormalities, genetic syndromes
- infections
- history of chronic hypertension, metabolic disorder before or during pregnancy, or the presence of high-risk factors such as heart diseases, diabetes, and renal diseases.
Who the study is looking for
- age 18-45 years
- healthy women with no previous adverse medical history and women with diagnosed preeclampsia
- singleton pregnancy
- people who have the full ability to give informed consent.
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Poznań University of Life Sciences Coordinator of this site? Confirm its status | Poznan | Poland | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.